1. Elewski B, Pariser D, Rich P, et al. Current and emerging options in the treatment of onychomycosis. Semin Cutan Med Surg. 2013;32(2 Suppl 1):S9–12.
2. Anacor Pharmaceuticals Inc. FDA approves Anacor Pharmaceuticals KERYDINTM (tavaborole) topical solution, 5 % for the treatment of onychomycosis of the toenails [media release]. 2014. http://investor.anacor.com/releasedetail.cfm?ReleaseID=858211 .
3. Anacor Pharmaceuticals Inc. Tavaborole KERYDINTM (tavaborole): US prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204427s000lbl.pdf . Accessed 24 Jul 2014.
4. Anacor Pharmaceuticals Inc. Anacor regains worldwide rights to AN2690 from Merck. [media release]. 2010. http://investor.anacor.com/releasedetail.cfm?ReleaseID=527619 .
5. Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007;316(5832):1759–61.